White Paper

Testing The CAR Risk Mitigation In Autologous CAR-T Therapy Clinical Trials In Oncology

GettyImages-1184502868 oncology patient

The field of Cell and Gene Therapy (CAGT) has witnessed a consistent rise in activity, driven by ongoing refinements in techniques and the establishment of standardized practices for patient selection and monitoring.

In this white paper, authors expand upon the initial publication in the CAGT Hot Buttons series titled “Starting the CAR: An Introduction to Autologous CAR-T Therapy.” The authors also delve into commonly encountered medical risks associated with the prevalent autologous Chimeric Antigen Receptor T-cell (CAR-T) therapies among patients with B-cell hematologic malignancies. These complications are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cardiovascular toxicity, tumor lysis syndrome, infections, hypogammaglobulinemia, and cytopenia.

Developed from a clinical trial perspective, consider the practices outlined in this whitepaper when managing these toxicities.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader